Related Experiment Video
Updated: Apr 19, 2026

Functional Characterization of Endogenously Expressed Human RYR1 Variants
Published on: June 9, 2021
Arrhythmogenic mechanisms in ryanodine receptor channelopathies
Yan-Ting Zhao1, Carmen R Valdivia, Georgina B Gurrola
1Center for Arrhythmia Research, Department of Internal Medicine, Cardiovascular Division, University of Michigan, Ann Arbor, MI, 48109, USA.
Abstract:
Ryanodine receptors (RyRs) are the calcium release channels of sarcoplasmic reticulum (SR) that provide the majority of calcium ions (Ca(2+)) necessary to induce contraction of cardiac and skeletal muscle cells. In their intracellular environment, RyR channels are regulated by a variety of cytosolic and luminal factors so that their output signal (Ca(2+)) induces finely-graded cell contraction without igniting cellular processes that may lead to aberrant electrical activity (ventricular arrhythmias) or cellular remodeling. The importance of RyR dysfunction has been recently highlighted with the demonstration that point mutations in RYR2, the gene encoding for the cardiac isoform of the RyR (RyR2), are associated with catecholaminergic polymorphic ventricular tachycardia (CPVT), an arrhythmogenic syndrome characterized by the development of adrenergically-mediated ventricular tachycardia in individuals with an apparently normal heart. Here we summarize the state of the field in regards to the main arrhythmogenic mechanisms triggered by RyR2 channels harboring mutations linked to CPVT. Most CPVT mutations characterized to date endow RyR2 channels with a gain of function, resulting in hyperactive channels that release Ca(2+) spontaneously, especially during diastole. The spontaneous Ca(2+) release is extruded by the electrogenic Na(+)/Ca(2+) exchanger, which depolarizes the external membrane (delayed afterdepolarization or DAD) and may trigger untimely action potentials. However, a rare set of CPVT mutations yield RyR2 channels that are intrinsically hypo-active and hypo-responsive to stimuli, and it is unclear whether these channels release Ca(2+) spontaneously during diastole. We discuss novel cellular mechanisms that appear more suitable to explain ventricular arrhythmias due to RyR2 loss-of-function mutations.
Insights
Ryanodine receptor (RyR2) mutations cause catecholaminergic polymorphic ventricular tachycardia (CPVT) through abnormal calcium (Ca2+) release. Most mutations cause hyperactive RyR2 channels, but some cause hypoactive channels, requiring new explanations for arrhythmias.
Area of Science:
- Cardiovascular Physiology
- Molecular Cardiology
- Ion Channel Function
Background:
- Ryanodine receptors (RyRs) are crucial calcium (Ca2+) release channels in muscle cells.
- Dysfunctional RyRs, particularly RyR2 mutations, are linked to cardiac arrhythmias like catecholaminergic polymorphic ventricular tachycardia (CPVT).
Purpose of the Study:
- To review arrhythmogenic mechanisms caused by RyR2 mutations in CPVT.
- To explore how both gain-of-function and loss-of-function RyR2 mutations contribute to ventricular arrhythmias.
Main Methods:
- Literature review of studies on RyR2 mutations and CPVT.
- Analysis of cellular mechanisms underlying RyR2-mediated calcium (Ca2+) release and its impact on cardiac electrical activity.
Main Results:
- Most CPVT-associated RyR2 mutations result in hyperactive channels causing spontaneous Ca2+ release during diastole.
- This spontaneous release can lead to delayed afterdepolarizations (DADs) and ventricular arrhythmias.
- A subset of CPVT mutations leads to hypoactive RyR2 channels, with unclear mechanisms for arrhythmia generation.
Conclusions:
- RyR2 channel dysfunction is a key driver of CPVT.
- While gain-of-function mutations are well-understood, novel mechanisms are needed to explain arrhythmias from loss-of-function RyR2 mutations.
More Related Videos
Related Concept Videos
Mechanism of Cardiac Arrhythmias
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Electrophysiology of Normal Cardiac Rhythm
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...

